{"entity":null,"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100VT69","filer_name":"久光製薬株式会社","filer_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","period_end":"2025-02-28","filed_date":"2025-05-23","sha256":"70a8c5be11904e957de978a2db2db89c22da1d6a0fda946c32754ed6a70499e3","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2025-02-28","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"住友不動産㈱","held_name_en":"Sumitomo Realty & Development Co., Ltd.","held_sec_code":"8830","match_status":"matched","shares":1151000,"book_value_yen":5992000000,"prior_shares":1151000,"prior_book_value_yen":5108000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.24454504459594395,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":2.1445418332396824,"pct_of_holder_assets":1.7465925122716197,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"TOPPANホールディングス㈱","held_name_en":"TOPPAN Holdings Inc.","held_sec_code":"7911","match_status":"matched","shares":1209841,"book_value_yen":5349000000,"prior_shares":1207481,"prior_book_value_yen":4302000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。取引先持株会を通じた取得による増加。","reciprocal":"有","pct_outstanding":0.41293243633076127,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":1.914411593124009,"pct_of_holder_assets":1.5591661128406031,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱シマノ","held_name_en":"SHIMANO INC.","held_sec_code":"7309","match_status":"matched","shares":154400,"book_value_yen":3152000000,"prior_shares":154400,"prior_book_value_yen":3220000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.17348353591805823,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":1.1281034476587917,"pct_of_holder_assets":0.9187682908344701,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"セーレン㈱","held_name_en":"SEIREN CO.,LTD.","held_sec_code":"3569","match_status":"matched","shares":1090000,"book_value_yen":2899000000,"prior_shares":1090000,"prior_book_value_yen":2792000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":1.859092838423035,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":1.037554535140494,"pct_of_holder_assets":0.8450219781501044,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":1583500,"book_value_yen":2570000000,"prior_shares":1583500,"prior_book_value_yen":3939000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.3370776949718268,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9198051587827076,"pct_of_holder_assets":0.7491226229202373,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"三浦工業㈱","held_name_en":"MIURA CO., LTD.","held_sec_code":"6005","match_status":"matched","shares":721500,"book_value_yen":2284000000,"prior_shares":721500,"prior_book_value_yen":2301000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.6236504213525734,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.817445518544632,"pct_of_holder_assets":0.6657572259726935,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日清食品ホールディングス㈱","held_name_en":"NISSIN FOODS HOLDINGS CO.,LTD.","held_sec_code":"2897","match_status":"matched","shares":716700,"book_value_yen":2173000000,"prior_shares":716700,"prior_book_value_yen":3136000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.2436277590835218,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7777185253053789,"pct_of_holder_assets":0.6334021243601852,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱クラレ","held_name_en":"KURARAY CO., LTD.","held_sec_code":"3405","match_status":"matched","shares":1067000,"book_value_yen":2002000000,"prior_shares":1067000,"prior_book_value_yen":1614000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.3294557157221174,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":0.7165174816665295,"pct_of_holder_assets":0.5835577786328074,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱大阪ソーダ","held_name_en":"OSAKA SODA CO., LTD.","held_sec_code":"4046","match_status":"matched","shares":1305000,"book_value_yen":1823000000,"prior_shares":261000,"prior_book_value_yen":3011000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。（注）２","reciprocal":"有","pct_outstanding":1.0369027326041986,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6524532313077339,"pct_of_holder_assets":0.5313815336901139,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["share split"],"note_refs":["2"],"share_ratio":5.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱オカムラ","held_name_en":"OKAMURA CORPORATION","held_sec_code":"7994","match_status":"matched","shares":713000,"book_value_yen":1377000000,"prior_shares":713000,"prior_book_value_yen":1560000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.7556110131884219,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4928294566707348,"pct_of_holder_assets":0.4013781524362517,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本ゼオン㈱","held_name_en":"ZEON CORPORATION","held_sec_code":"4205","match_status":"matched","shares":792800,"book_value_yen":1169000000,"prior_shares":792800,"prior_book_value_yen":1006000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.39903049682175834,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.41838608195213434,"pct_of_holder_assets":0.34074877283803795,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"エーザイ㈱","held_name_en":"Eisai Co., Ltd.","held_sec_code":"4523","match_status":"matched","shares":251700,"book_value_yen":1084000000,"prior_shares":251700,"prior_book_value_yen":1574000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.08921863542000598,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.38796451055270625,"pct_of_holder_assets":0.31597234367530636,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"倉敷紡績㈱","held_name_en":"KURABO INDUSTRIES LTD.","held_sec_code":"3106","match_status":"matched","shares":158300,"book_value_yen":976000000,"prior_shares":158300,"prior_book_value_yen":503000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.9282987444803462,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.34931121983343294,"pct_of_holder_assets":0.28449170426854153,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"江崎グリコ㈱","held_name_en":"Ezaki Glico Co., Ltd.","held_sec_code":"2206","match_status":"matched","shares":208000,"book_value_yen":946000000,"prior_shares":208000,"prior_book_value_yen":929000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.32671028238465016,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":0.3385741946336348,"pct_of_holder_assets":0.27574708221110683,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱三菱UFJフィナンシャル・グループ","held_name_en":"Mitsubishi UFJ Financial Group, Inc.","held_sec_code":"8306","match_status":"matched","shares":474800,"book_value_yen":903000000,"prior_shares":474800,"prior_book_value_yen":732000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。","reciprocal":"有","pct_outstanding":0.0041184493727232955,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.32318445851392413,"pct_of_holder_assets":0.2632131239287838,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"レンゴー㈱","held_name_en":"Rengo Co., Ltd.","held_sec_code":"3941","match_status":"matched","shares":1122000,"book_value_yen":896000000,"prior_shares":1122000,"prior_book_value_yen":1120000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.44964906513530994,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.32067915263397123,"pct_of_holder_assets":0.2611727121153824,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アルフレッサホールディングス㈱","held_name_en":"Alfresa Holdings Corporation","held_sec_code":"2784","match_status":"matched","shares":396284,"book_value_yen":790000000,"prior_shares":396284,"prior_book_value_yen":886000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.21749515377303194,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.28274166359468444,"pct_of_holder_assets":0.2302750475124465,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"新日本空調㈱","held_name_en":"Shin Nippon Air Technologies Co., Ltd.","held_sec_code":"1952","match_status":"matched","shares":412200,"book_value_yen":680000000,"prior_shares":206100,"prior_book_value_yen":583000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。（注）３","reciprocal":"有","pct_outstanding":0.9095472674415398,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2433725711954246,"pct_of_holder_assets":0.1982114333018527,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["share split"],"note_refs":["3"],"share_ratio":2.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本新薬㈱","held_name_en":"Nippon Shinyaku Co., Ltd.","held_sec_code":"4516","match_status":"matched","shares":165000,"book_value_yen":649000000,"prior_shares":165000,"prior_book_value_yen":787000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.24488456913168563,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.23227764515563318,"pct_of_holder_assets":0.18917532384250352,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ふくおかフィナンシャルグループ","held_name_en":"Fukuoka Financial Group, Inc.","held_sec_code":"8354","match_status":"matched","shares":142269,"book_value_yen":558000000,"prior_shares":142269,"prior_book_value_yen":552000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。","reciprocal":"有","pct_outstanding":0.07515119417787822,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.19970866871624549,"pct_of_holder_assets":0.162649970268285,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"王子ホールディングス㈱","held_name_en":"Oji Holdings Corporation","held_sec_code":"3861","match_status":"matched","shares":788000,"book_value_yen":488000000,"prior_shares":788000,"prior_book_value_yen":462000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.08412766027822745,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17465560991671647,"pct_of_holder_assets":0.14224585213427077,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱西日本フィナンシャルホールディングス","held_name_en":"Nishi-Nippon Financial Holdings, Inc.","held_sec_code":"7189","match_status":"matched","shares":243900,"book_value_yen":479000000,"prior_shares":243900,"prior_book_value_yen":461000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。","reciprocal":"有","pct_outstanding":0.1750267159731541,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17143450235677704,"pct_of_holder_assets":0.13962246551704036,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱山口フィナンシャルグループ","held_name_en":"Yamaguchi Financial Group, Inc.","held_sec_code":"8418","match_status":"matched","shares":263000,"book_value_yen":432000000,"prior_shares":263000,"prior_book_value_yen":399000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。","reciprocal":"有","pct_outstanding":0.12381748650916681,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.15461316287709329,"pct_of_holder_assets":0.12592255762705937,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱リコー","held_name_en":"RICOH COMPANY,LTD.","held_sec_code":"7752","match_status":"matched","shares":265000,"book_value_yen":430000000,"prior_shares":265000,"prior_book_value_yen":329000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため","reciprocal":"有","pct_outstanding":0.04652039080540942,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.15389736119710673,"pct_of_holder_assets":0.12533958282323038,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"西部ガスホールディングス㈱","held_name_en":"ＳＡＩＢＵ ＧＡＳ ＨＯＬＤＩＮＧＳ ＣＯ.,ＬＴＤ.","held_sec_code":"9536","match_status":"matched","shares":244500,"book_value_yen":404000000,"prior_shares":244500,"prior_book_value_yen":463000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.6595973833758313,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.14459193935728168,"pct_of_holder_assets":0.11776091037345365,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"大木ヘルスケアホールディングス㈱","held_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","held_sec_code":"3417","match_status":"matched","shares":467026,"book_value_yen":400000000,"prior_shares":463448,"prior_book_value_yen":469000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。取引先持株会を通じた取得による増加。","reciprocal":"有","pct_outstanding":3.4244212903556948,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1431603359973086,"pct_of_holder_assets":0.1165949607657957,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":176458,"book_value_yen":387000000,"prior_shares":176458,"prior_book_value_yen":399000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.08485587624370257,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.13850762507739606,"pct_of_holder_assets":0.11280562454090734,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"養命酒製造㈱","held_name_en":"YOMEISHU SEIZO CO., LTD.","held_sec_code":"2540","match_status":"matched","shares":139500,"book_value_yen":365000000,"prior_shares":139500,"prior_book_value_yen":264000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":1.0018600843142464,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1306338065975441,"pct_of_holder_assets":0.10639290169878858,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"NOK㈱","held_name_en":"NOK CORPORATION","held_sec_code":"7240","match_status":"matched","shares":157400,"book_value_yen":358000000,"prior_shares":157400,"prior_book_value_yen":333000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.09515125352678513,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1281285007175912,"pct_of_holder_assets":0.10435248988538716,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"西日本鉄道㈱","held_name_en":"Nishi-Nippon Railroad Co.，Ltd.","held_sec_code":"9031","match_status":"matched","shares":163400,"book_value_yen":354000000,"prior_shares":163400,"prior_book_value_yen":393000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.20986120057611396,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1266968973576181,"pct_of_holder_assets":0.1031865402777292,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東邦ホールディングス㈱","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":82962,"book_value_yen":347000000,"prior_shares":82962,"prior_book_value_yen":262000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.1325679391912611,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1241915914776652,"pct_of_holder_assets":0.10114612846432777,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"朝日印刷㈱","held_name_en":"ASAHI PRINTING CO.,LTD.","held_sec_code":"3951","match_status":"matched","shares":336932,"book_value_yen":300000000,"prior_shares":335044,"prior_book_value_yen":304000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。取引先持株会を通じた取得による増加。","reciprocal":"有","pct_outstanding":1.5852916224330442,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10737025199798143,"pct_of_holder_assets":0.08744622057434678,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"稲畑産業㈱","held_name_en":"Inabata & Co.,Ltd.","held_sec_code":"8098","match_status":"matched","shares":92300,"book_value_yen":287000000,"prior_shares":92300,"prior_book_value_yen":294000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.16892934684721742,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10271754107806891,"pct_of_holder_assets":0.08365688434945842,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ホクト㈱","held_name_en":"HOKUTO CORPORATION","held_sec_code":"1379","match_status":"matched","shares":146400,"book_value_yen":278000000,"prior_shares":146400,"prior_book_value_yen":263000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.4601756337001956,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09949643351812947,"pct_of_holder_assets":0.08103349773222801,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱佐賀銀行","held_name_en":"THE BANK OF SAGA LTD.","held_sec_code":"8395","match_status":"matched","shares":96700,"book_value_yen":214000000,"prior_shares":96700,"prior_book_value_yen":198000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。","reciprocal":"有","pct_outstanding":0.5725007014169659,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07659077975856009,"pct_of_holder_assets":0.0623783040097007,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱筑邦銀行","held_name_en":"The Chikuho Bank, Ltd.","held_sec_code":"8398","match_status":"matched","shares":140800,"book_value_yen":193000000,"prior_shares":140800,"prior_book_value_yen":216000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。","reciprocal":"有","pct_outstanding":2.255535513470737,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0690748621187014,"pct_of_holder_assets":0.05625706856949643,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱スズケン","held_name_en":"SUZUKEN CO.,LTD.","held_sec_code":"9987","match_status":"matched","shares":40462,"book_value_yen":192000000,"prior_shares":40462,"prior_book_value_yen":180000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.056144817273610335,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06871696127870812,"pct_of_holder_assets":0.055965581167581935,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":172500,"book_value_yen":151000000,"prior_shares":172500,"prior_book_value_yen":138000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.8207602380918395,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.054043026838983994,"pct_of_holder_assets":0.04401459768908788,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱日本触媒","held_name_en":"NIPPON SHOKUBAI CO., LTD.","held_sec_code":"4114","match_status":"matched","shares":66400,"book_value_yen":120000000,"prior_shares":16600,"prior_book_value_yen":93000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。(注)４","reciprocal":"有","pct_outstanding":0.04377285054867686,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.042948100799192576,"pct_of_holder_assets":0.03497848822973871,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["share split"],"note_refs":["4"],"share_ratio":4.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱バローホールディングス","held_name_en":"VALOR HOLDINGS CO.,LTD.","held_sec_code":"9956","match_status":"matched","shares":50000,"book_value_yen":113000000,"prior_shares":50000,"prior_book_value_yen":121000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"無","pct_outstanding":0.09493214430696012,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.040442794919239675,"pct_of_holder_assets":0.03293807641633729,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"荒川化学工業㈱","held_name_en":"ARAKAWA CHEMICAL INDUSTRIES, LTD.","held_sec_code":"4968","match_status":"matched","shares":91000,"book_value_yen":103000000,"prior_shares":91000,"prior_book_value_yen":102000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.4586970986148356,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03686378651930696,"pct_of_holder_assets":0.030023202397192392,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"高砂香料工業㈱","held_name_en":"TAKASAGO INTERNATIONAL CORPORATION","held_sec_code":"4914","match_status":"matched","shares":13200,"book_value_yen":89000000,"prior_shares":13200,"prior_book_value_yen":43000000,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.06772531249459672,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03185317475940116,"pct_of_holder_assets":0.025942378770389542,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱三井住友フィナンシャルグループ","held_name_en":"Sumitomo Mitsui Financial Group, Inc.","held_sec_code":"8316","match_status":"matched","shares":20100,"book_value_yen":76000000,"prior_shares":6700,"prior_book_value_yen":55000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。(注)５","reciprocal":"有","pct_outstanding":0.0005188114772015996,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.027200463839488633,"pct_of_holder_assets":0.022153042545501184,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["share split"],"note_refs":["5"],"share_ratio":3.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱マツキヨココカラ＆カンパニー ","held_name_en":"MatsukiyoCocokara&Co.","held_sec_code":"3088","match_status":"matched","shares":25500,"book_value_yen":58000000,"prior_shares":25500,"prior_book_value_yen":63000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.006312494781361545,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.020758248719609743,"pct_of_holder_assets":0.016906269311040376,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱りそなホールディングス","held_name_en":"Resona Holdings, Inc.","held_sec_code":"8308","match_status":"matched","shares":38600,"book_value_yen":44000000,"prior_shares":38600,"prior_book_value_yen":31000000,"purpose_ja":"金融取引先であり、財務活動における取引関係の強化を図るため。","reciprocal":"有","pct_outstanding":0.0016736145038478362,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.015747636959703944,"pct_of_holder_assets":0.012825445684237527,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"中外製薬㈱","held_name_en":"CHUGAI PHARMACEUTICAL CO., LTD.","held_sec_code":"4519","match_status":"matched","shares":3900,"book_value_yen":29000000,"prior_shares":3900,"prior_book_value_yen":23000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.00023700630164569757,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":0.010379124359804872,"pct_of_holder_assets":0.008453134655520188,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"第一三共㈱","held_name_en":"DAIICHI SANKYO COMPANY, LIMITED","held_sec_code":"4568","match_status":"matched","shares":8277,"book_value_yen":28000000,"prior_shares":8277,"prior_book_value_yen":41000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.0004428087326562146,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.010021223519811601,"pct_of_holder_assets":0.0081616472536057,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"有機合成薬品工業㈱","held_name_en":"YUKI GOSEI KOGYO CO., LTD.","held_sec_code":"4531","match_status":"matched","shares":100000,"book_value_yen":26000000,"prior_shares":100000,"prior_book_value_yen":33000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.46419005797733826,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.009305421839825058,"pct_of_holder_assets":0.007578672449776721,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"CBグループマネジメント㈱","held_name_en":"CB GROUP MANAGEMENT Co., Ltd.","held_sec_code":null,"match_status":"matched","shares":3195,"book_value_yen":25000000,"prior_shares":3103,"prior_book_value_yen":15000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。取引先持株会を通じた取得による増加。","reciprocal":"有","pct_outstanding":0.14632149144419998,"pct_unavailable":null,"pct_basis_period_end":"2024-03-31","pct_share_classes":1,"pct_of_holder_equity":0.008947520999831787,"pct_of_holder_assets":0.007287185047862231,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"塩野義製薬㈱","held_name_en":"Shionogi & Co., Ltd.","held_sec_code":"4507","match_status":"matched","shares":9000,"book_value_yen":20000000,"prior_shares":3000,"prior_book_value_yen":22000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。(注)６","reciprocal":"無","pct_outstanding":0.0010468920453472457,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00715801679986543,"pct_of_holder_assets":0.0058297480382897855,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share split"],"note_refs":["6"],"share_ratio":3.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱バイタルケーエスケー・ホールディングス","held_name_en":"VITAL KSK HOLDINGS,INC.","held_sec_code":"3151","match_status":"matched","shares":13200,"book_value_yen":15000000,"prior_shares":13200,"prior_book_value_yen":17000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"無","pct_outstanding":0.02728407158381307,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.005368512599899072,"pct_of_holder_assets":0.004372311028717339,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日東電工㈱","held_name_en":"NITTO DENKO CORPORATION","held_sec_code":"6988","match_status":"matched","shares":5000,"book_value_yen":14000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。(注)７","reciprocal":"無","pct_outstanding":0.0007194920098613575,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0050106117599058005,"pct_of_holder_assets":0.00408082362680285,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share split"],"note_refs":["7"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アルテック㈱","held_name_en":"ALTECH CO., LTD.","held_sec_code":"9972","match_status":"matched","shares":50000,"book_value_yen":10000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.3631187543574251,"pct_unavailable":null,"pct_basis_period_end":"2024-11-30","pct_share_classes":1,"pct_of_holder_equity":0.003579008399932715,"pct_of_holder_assets":0.0029148740191448927,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ロート製薬㈱","held_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4527","match_status":"matched","shares":4000,"book_value_yen":8000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.0017701902702288383,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0028632067199461718,"pct_of_holder_assets":0.002331899215315914,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アステラス製薬㈱","held_name_en":"Astellas Pharma Inc.","held_sec_code":"4503","match_status":"matched","shares":4615,"book_value_yen":6000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.0002550889449964808,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0021474050399596287,"pct_of_holder_assets":0.0017489244114869355,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"武田薬品工業㈱","held_name_en":"Takeda Pharmaceutical Company Limited","held_sec_code":"4502","match_status":"matched","shares":1200,"book_value_yen":5000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"無","pct_outstanding":7.598711012667306e-05,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0017895041999663574,"pct_of_holder_assets":0.0014574370095724464,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":1000,"book_value_yen":3000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.0023361710413610905,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0010737025199798144,"pct_of_holder_assets":0.0008744622057434677,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キリンＨＤ㈱","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":1000,"book_value_yen":2000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.0007158016799865429,"pct_of_holder_assets":0.0005829748038289785,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ニチバン㈱","held_name_en":"NICHIBAN CO., LTD.","held_sec_code":"4218","match_status":"matched","shares":500,"book_value_yen":1000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.002456096537562116,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00035790083999327147,"pct_of_holder_assets":0.00029148740191448926,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱電通","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":200,"book_value_yen":0,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"医薬品事業の取引先であり、取引関係維持・強化を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ワコールホールディングス","held_name_en":"WACOAL HOLDINGS CORP.","held_sec_code":"3591","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":70500,"prior_book_value_yen":257000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱テレビ東京ホールディングス","held_name_en":"TV TOKYO Holdings Corporation","held_sec_code":"9413","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":137300,"prior_book_value_yen":405000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ヤクルト本社","held_name_en":"YAKULT HONSHA CO.,LTD.","held_sec_code":"2267","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":902200,"prior_book_value_yen":2912000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"コクヨ㈱","held_name_en":"KOKUYO CO., LTD.","held_sec_code":"7984","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":290000,"prior_book_value_yen":686000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ソニーグループ㈱","held_name_en":"SONY GROUP CORPORATION","held_sec_code":"6758","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":2200,"prior_book_value_yen":28000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"参天製薬㈱","held_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4536","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":31525,"prior_book_value_yen":46000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"NISSHA㈱","held_name_en":"Nissha Co., Ltd.","held_sec_code":"7915","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":35900,"prior_book_value_yen":53000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ダイダン㈱","held_name_en":"DAI-DAN CO., LTD.","held_sec_code":"1980","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":534000,"prior_book_value_yen":991000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"大成建設㈱","held_name_en":"TAISEI CORPORATION","held_sec_code":"1801","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":276200,"prior_book_value_yen":1300000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"（注）１．定量的な保有効果につきましては記載が困難ですが、当社保有の政策保有株式について、取引に伴う便益や配当等による経済合理性等による定量的検証結果取引の状況等及び配当等による経済合理性等を総合的に勘案したうえで、取締役会において保有の合理性を検証しています。"},{"holder_table":"reporting","note_no":"2","text_ja":"２．㈱大阪ソーダは、2024年10月１日を基準日として、１株につき５株の割合で株式分割を行っています。"},{"holder_table":"reporting","note_no":"3","text_ja":"３．新日本空調㈱は、2025年12月31日を基準日として、１株につき２株の割合で株式分割を行っています。"},{"holder_table":"reporting","note_no":"4","text_ja":"４．㈱日本触媒は、2024年４月１日を基準日として、１株につき４株の割合で株式分割を行っています。"},{"holder_table":"reporting","note_no":"5","text_ja":"５．㈱三井住友フィナンシャルグループは、2024年10月１日を基準日として、１株につき３株の割合で株式分割を行っています。"},{"holder_table":"reporting","note_no":"6","text_ja":"６．塩野義製薬㈱は、2024年10月１日を基準日として、１株につき３株の割合で株式分割を行っています。"},{"holder_table":"reporting","note_no":"7","text_ja":"７．日東電工㈱は、2024年10月１日を基準日として、１株につき５株の割合で株式分割を行っています。"},{"holder_table":"reporting","note_no":"8","text_ja":"８．「―」は、当該銘柄を保有していないことを示しております。「*」は、当該銘柄の貸借対照表計上額が当社の資本金額の100分の１以下であり、かつ貸借対照表計上額の大きい順の60銘柄に該当しないために記載を省略していることを示しています。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":4,"acquisition_cost_yen":15000000,"issues_decreased":9,"sale_proceeds_yen":7711000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":1,"acquisition_cost_yen":100000000,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":51710000000,"listed_yen":45154000000,"unlisted_yen":6556000000,"listed_issues":62,"unlisted_issues":15,"equity_yen":279407000000,"equity_basis":"jgaap_consolidated","total_assets_yen":343068000000,"assets_basis":"jgaap_consolidated","pct_of_equity":18.507052436052067,"pct_of_assets":15.07281355299824,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":45154000000,"issue_count":62,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":6556000000,"issue_count":15,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-02-28","policy_total_yen":45458000000,"equity_yen":254885000000,"equity_basis":"jgaap_consolidated","pct_of_equity":17.83470977107323,"pct_of_assets":15.009674500921223},{"year":"2023","period_end":"2023-02-28","policy_total_yen":53377000000,"equity_yen":258408000000,"equity_basis":"jgaap_consolidated","pct_of_equity":20.656094238568464,"pct_of_assets":17.00353915206886},{"year":"2024","period_end":"2024-02-29","policy_total_yen":59363000000,"equity_yen":267082000000,"equity_basis":"jgaap_consolidated","pct_of_equity":22.226507215012617,"pct_of_assets":18.055593575015436},{"year":"2025","period_end":"2025-02-28","policy_total_yen":51710000000,"equity_yen":279407000000,"equity_basis":"jgaap_consolidated","pct_of_equity":18.507052436052067,"pct_of_assets":15.07281355299824}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-02-28","named_holdings":62,"book_value_yen":44367000000},{"year":"2023","period_end":"2023-02-28","named_holdings":61,"book_value_yen":46825000000},{"year":"2024","period_end":"2024-02-29","named_holdings":62,"book_value_yen":52819000000},{"year":"2025","period_end":"2025-02-28","named_holdings":69,"book_value_yen":45126000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}